​

BioMarin Pharmaceutical (BMRN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BMRN Stock Forecast

BioMarin Pharmaceutical (BMRN) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $89.93, with a high of $120.00 and a low of $50.00. This represents a 59.03% increase from the last price of $56.55.

$50 $64 $78 $92 $106 $120 High: $120 Avg: $89.93 Low: $50 Last Closed Price: $56.55

BMRN Stock Rating

BioMarin Pharmaceutical stock's rating consensus is Buy, based on 41 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 28 Buy (68.29%), 13 Hold (31.71%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 41 13 28 0 Strong Sell Sell Hold Buy Strong Buy

BMRN Price Target Upside V Benchmarks

TypeNameUpside
StockBioMarin Pharmaceutical59.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts4830
Avg Price Target$73.00$89.63$85.93
Last Closing Price$56.55$56.55$56.55
Upside/Downside29.09%58.50%51.95%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 266146--26
May, 265145--24
Apr, 264145--23
Mar, 264145--23
Feb, 264146--24
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 22, 2026Canaccord Genuity$111.00$54.10105.18%96.29%
May 18, 2026Leerink Partners$62.00$49.6724.82%9.64%
May 18, 2026H.C. Wainwright$50.00$50.15-0.30%-11.58%
May 11, 2026Goldman Sachs$69.00$54.0627.64%22.02%
May 05, 2026Evercore ISI$120.00$54.36120.75%112.20%
May 05, 2026William PickeringTudor Pickering$82.00$55.4647.85%45.00%
Apr 27, 2026Sean LaamanMorgan Stanley$120.00$53.18125.65%112.20%
Mar 12, 2026Akash TewariJefferies$103.00$59.8672.07%82.14%
Mar 03, 2026Eliana MerleBarclays$105.00$59.7475.76%85.68%
Mar 02, 2026Ilya ZubkovLoop Capital Markets$105.00$60.4773.64%85.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 22, 2026H.C. WainwrightNeutralNeutralhold
May 18, 2026CitigroupNeutralBuyinitialise
May 05, 2026Evercore ISIOutperformOutperformhold
May 05, 2026BernsteinOutperformOutperformhold
Mar 16, 2026Wolfe ResearchOutperformOutperformhold
Mar 12, 2026JefferiesBuyBuyhold
Mar 09, 2026Leerink PartnersMarket PerformMarket Performhold
Mar 03, 2026BarclaysOverweightOverweighthold
Feb 18, 2026Wells FargoOverweightOverweighthold
Dec 22, 2025H.C. WainwrightNeutralNeutralhold

Financial Forecast

EPS Forecast

$-1 $0 $1 $2 $3 $4 $5 $6 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.35$0.76$0.89$2.25$1.82---
Avg Forecast$-0.35$0.69$0.98$2.26$3.22$4.07$4.97$5.99
High Forecast$-0.32$0.74$1.01$2.31$3.90$5.58$6.90$6.50
Low Forecast$-0.37$0.65$0.96$2.20$2.81$2.84$3.95$5.59
Surprise %-10.14%-9.18%-0.44%-43.48%---

Revenue Forecast

$2B $2B $3B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.85B$2.10B$2.42B$2.85B$3.22B---
Avg Forecast$1.84B$2.10B$2.41B$2.82B$3.10B$3.40B$3.64B$3.84B
High Forecast$1.92B$2.21B$2.50B$2.83B$3.24B$3.41B$3.65B$4.09B
Low Forecast$1.73B$2.00B$2.39B$2.80B$2.98B$3.39B$3.63B$3.64B
Surprise %0.23%-0.06%0.27%1.24%3.79%---

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-64.08M$141.56M$167.65M$426.86M$348.90M---
Avg Forecast$-20.04M$91.20M$167.65M$432.46M$598.00M$814.68M$974.91M$1.15B
High Forecast$16.63M$154.19M$336.98M$442.98M$747.09M$1.07B$1.32B$1.25B
Low Forecast$-56.71M$28.22M$-1.69M$421.94M$538.46M$543.69M$756.58M$1.07B
Surprise %219.76%55.21%--1.30%-41.66%---

BMRN Forecast FAQ

Is BioMarin Pharmaceutical stock a buy?

BioMarin Pharmaceutical stock has a consensus rating of Buy, based on 41 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 28 Buy, 13 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioMarin Pharmaceutical is a favorable investment for most analysts.

What is BioMarin Pharmaceutical's price target?

BioMarin Pharmaceutical's price target, set by 41 Wall Street analysts, averages $89.93 over the next 12 months. The price target range spans from $50 at the low end to $120 at the high end, suggesting a potential 59.03% change from the previous closing price of $56.55.

How does BioMarin Pharmaceutical stock forecast compare to its benchmarks?

BioMarin Pharmaceutical's stock forecast shows a 59.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BioMarin Pharmaceutical over the past three months?

  • June 2026: 23.08% Strong Buy, 53.85% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 20.83% Strong Buy, 58.33% Buy, 20.83% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 17.39% Strong Buy, 60.87% Buy, 21.74% Hold, 0% Sell, 0% Strong Sell.

What is BioMarin Pharmaceutical’s EPS forecast?

BioMarin Pharmaceutical's average annual EPS forecast for its fiscal year ending in December 2026 is $4.07, marking a 123.63% increase from the reported $1.82 in 2025. Estimates for the following years are $4.97 in 2027, and $5.99 in 2028.

What is BioMarin Pharmaceutical’s revenue forecast?

BioMarin Pharmaceutical's average annual revenue forecast for its fiscal year ending in December 2026 is $3.4B, reflecting a 5.53% increase from the reported $3.22B in 2025. The forecast for 2027 is $3.64B, and $3.84B for 2028.

What is BioMarin Pharmaceutical’s net income forecast?

BioMarin Pharmaceutical's net income forecast for the fiscal year ending in December 2026 stands at $814.68M, representing an 133.50% increase from the reported $348.9M in 2025. Projections indicate $974.91M in 2027, and $1.15B in 2028.